Drugs / OKG-0301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03856645 | Feb 2019 → Jun 2022 | viral conjunctivitis | Okogen | Unknown | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-04-29 | Okogen | Results Safe, Effective and Dose Responsive Anti-Viral Activity of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis–Phase 2 Interim Analysis Results from RUBY Clinical Trial okogen.com ↗
Okogen, a clinical-stage specialty ophthalmic biotechnology company announced the interim analysis results from RUBY, the company’s Phase 2, double-masked, placebo-controlled clinical trial evaluating the safety and efficacy of OKG-0301 in patients with acute adenoviral conjunctivitis. |
| 2017-05-18 | Okogen | Results OKG-0301, a Novel Ribonuclease, Demonstrates Antiviral Activity Against Adenovirus in the Ad5/NZW Rabbit Ocular Model. okogen.com ↗ |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OKG-0301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03856645 ↗ |
| Modality | Protein / enzyme biologic | “OKG-0301 is a novel ophthalmic solution with a potent ribonuclease that has broad-spectrum antiviral properties relevant for the treatment of acute adenoviral conjunctivitis.” NCT03856645 ↗ |
| Route | Other | “OKG-0301 is a novel ophthalmic solution with a potent ribonuclease that has broad-spectrum antiviral properties relevant for the treatment of acute adenoviral conjunctivitis.” NCT03856645 ↗ |